TARPLIN, DOWNS & YOUNG, LLC

Lobbying for HANSA BIOPHARMA · Biopharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $60,000.00 income · posted Jan 20, 2026

Lobbying activity 2

Health Issues

Kidney issues, access to innovation, rare disease issues, organ rejection

Budget/Appropriations

Federal budget issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.